SCHEDULE: State Street Corp. Discloses Stake in Protagonist Therapeutics

State Street Corporation has filed a Schedule 13G, reporting beneficial ownership of 5.2% of Protagonist Therapeutics Inc. common stock as of June 30, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating it beneficially owns 3,321,554 shares of Protagonist Therapeutics Inc. common stock.
• This ownership stake represents 5.2% of the class of securities.
• The filing date for this event is June 30, 2026.
• State Street Corporation is identified as a holder of investment securities, with its subsidiaries acting as investment advisers.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of influencing control.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership without providing new operational or financial performance data.

Positives

• State Street Corporation's investment indicates confidence from a major financial institution in Protagonist Therapeutics.
• The filing confirms a significant institutional holding, which can sometimes lend stability to a stock.

Negatives

• The filing is a routine disclosure of beneficial ownership and does not contain any new operational or financial performance data for Protagonist Therapeutics.
• The disclosure does not provide insight into the specific investment strategy or conviction level of State Street Corporation beyond the reported percentage.

Risks

• As a Schedule 13G filing, it indicates passive investment, meaning State Street Corporation is not seeking to control or influence the company's management or operations.
• Changes in beneficial ownership by large institutional investors can sometimes precede or coincide with shifts in market sentiment, though this filing itself does not indicate such a shift.

Future Outlook

This filing does not contain forward-looking statements or guidance from Protagonist Therapeutics. It is a disclosure of beneficial ownership by State Street Corporation.

Management Comments

• State Street Corporation certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing places Protagonist Therapeutics within the portfolio of a major financial services firm, State Street Corporation, which manages substantial assets across various sectors.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor, which may be viewed positively by some, but the passive nature of the holding limits direct impact on corporate strategy.
• Management: The passive nature of State Street's holding means no immediate pressure or influence on management decisions.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• State Street Corporation will continue to hold its position in Protagonist Therapeutics Inc. unless it decides to change its investment strategy.
• Protagonist Therapeutics Inc. will continue its operations and strategic initiatives, with State Street Corporation as a significant shareholder.

Key Dates

Keywords

State Street Corporation, Protagonist Therapeutics, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Adviser